Brisbane biotech Vaxxas secures US patent for needle-free vaccine technology

Manufacturing News

Brisbane-based clinical-stage biotechnology company Vaxxas secured a new patent from the United States patent office covering its proprietary manufacturing technology for needle-free vaccine patches, the company announced on Wednesday. The patent covers Vaxxas’ printhead system that dispenses dried vaccine formulations onto the company’s high-density microarray patch (HD-MAP), which features thousands of microscopic projections on a…

Australian company develops vaccine ‘patch’ that could replace needles

Manufacturing News

Brisbane-based biotechnology company Vaxxas published new research on Wednesday showing promising results for its needle-free vaccine delivery technology. The company’s high-density microarray patch (HD-MAP) – a small patch containing thousands of tiny projections coated with vaccine – successfully delivered a DNA-based COVID-19 vaccine in animal testing, according to research published in the science journal Heliyon.…

Research shows potential for a new “off-the-shelf” cell-based therapy for tissue healing

Manufacturing News

Researchers from Monash University, led by Associate Professor Mikaël Martino from the university’s Australian Regenerative Medical Research Institute, have discovered a cell in blood which can rapidly promote healing, suggesting potential in off-the-shelf therapies. The group’s research showed cells known as Regulatory T cells “rapidly becoming a cell type specific for the injury it needs…

CSL’s mRNA Covid-19 vaccine approved for sale in Japan

Manufacturing News, Technology

Japan’s Ministry of Health, Labor and Welfare has approved biotechnology manufacturer CSL and Arcturus Therapeutics’ new Covid-19 vaccine against the JN.1 strain of the disease. The ministry approved for sale the two companies’ ‘updated self-amplifying mRNA Covid-19 vaccine for protection against JN.1 Strain’, to be distributed in Japan by Meiji Seika Pharma. According to CSL…